Results of Gadolinium Clinical Trial Expected Soon
Currently, researchers are performing a clinical trial examining gadolinium efficacy along with possible side effects. GE Healthcare will publish the preliminary findings at the end of the month. However, the study isn’t scheduled for completion until 2019.
Gadolinium is a chemical element carrying the atomic number 64 and the atomic symbol Gd. Belonging to a group of elements in the periodic table called Lanthanides, the chemical is a rare earth element typically used in microwave applications, color TV tubes, synthetic gemstones, compact discs, and computer memory. The medical community uses this chemical element as an injectable contrast agent when patients undergo magnetic resonance Imaging (MRI) and magnetic resonance angiography (MRA) scans.
Gadolinium Clinical Trial
The study includes 5,400 participants in 17 radiology centers. Researchers inject each one with a 0.5 mmol/ml Clariscan injection. Then, they are using a number of medical equipment to collect data. This includes ultrasound, MRI, CT scans, fluoroscopy, X-ray, single-photon emission CT [SPECT], and positron emission tomography [PET] examinations. Then, a radiologist will assess the image quality using a 4-point Likert scale. The number 1 indicates the poorest image quality, and then, the number 4 is an excellent image. Also, researchers are using the Likert scale to assess the quality of the scans showing clarity of lesions.
The study also includes a customer satisfaction survey where patients and doctors can inform researchers of any issues with Clariscan.
Researchers chose male and female participants needing contrast-enhanced magnetic imaging. However, they excluded patients using liver-specific contrast agents. But, they accepted all ages. The initial results are expected on December 31. Yet, the study will not end until January 31, 2019.
Free Case Evaluation
A gadolinium lawsuit may be an option for patients suffering from gadolinium retention and related complications. Gadolinium, used in dyes to increase the clarity of MRI and MRA scans, can create chemical element retention in the body, Therefore, this increases the risk of gadolinium deposition disease and nephrogenic systemic fibrosis. These conditions are accompanied by symptoms that include severe physical pain and cognitive difficulties. Affected patients and their loved ones may be able to file a lawsuit and recover damages.
For more information, contact The Michael Brady Lynch Firm. We offer free, confidential, no obligation consultations. We have over 20 years of experience helping consumers injured by unsafe products manufactured by large companies.